menu
    • menu
    [{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Resolve Therapeutics

    Menu

    Resolve Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial

                            Details : RSLV-132 is a safe, novel, targeted biologic drug designed to remove pro-inflammatory nucleic acids from the circulation of patients, which is one of the key triggers of multiple pro-inflammatory cascades.

                            Product Name : RSLV-132

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 11, 2022

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patien...

                            Details : Based on previous positive phase 2 clinical trial with RSLV-132 in autoimmune fatigue, removing circulating RNA in long covid patients will have a similar improvement in their fatigue and brain fog.

                            Product Name : RSLV-132

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 23, 2021

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Resolve Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resolve Therapeutics Publishes Positive Sjogren’s Syndrome Clinical Trial Results

                            Details : The Phase 2 study demonstrated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the RSLV-132 group, but not the placebo group.

                            Product Name : RSLV-132

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 12, 2020

                            Lead Product(s) : RSLV-132

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth